Final 3-Year Outcomes of a Randomized Trial Comparing a Self-Expanding to a Balloon-Expandable Transcatheter Aortic Valve.

Lanz, Jonas; Möllmann, Helge; Kim, Won-Keun; Burgdorf, Christof; Linke, Axel; Redwood, Simon; Hilker, Michael; Joner, Michael; Thiele, Holger; Conzelmann, Lars; Conradi, Lenard; Kerber, Sebastian; Thilo, Christian; Toggweiler, Stefan; Prendergast, Bernard; Husser, Oliver; Stortecky, Stefan; Deckarm, Sarah; Künzi, Arnaud; Heg, Dik; ... (2023). Final 3-Year Outcomes of a Randomized Trial Comparing a Self-Expanding to a Balloon-Expandable Transcatheter Aortic Valve. Circulation: Cardiovascular interventions, 16(7), e012873. Lippincott Williams & Wilkins 10.1161/CIRCINTERVENTIONS.123.012873

Text Lanz_CircCardiovascInterv_2023.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

BACKGROUND

In the SCOPE I trial (Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis), transcatheter aortic valve implantation with the self-expanding ACURATE neo (NEO) did not meet noninferiority compared with the balloon-expandable SAPIEN 3 (S3) device regarding a composite end point at 30 days due to higher rates of prosthetic valve regurgitation and acute kidney injury. Data on long-term durability of NEO are scarce. Here, we report whether early differences between NEO and S3 translate into differences in clinical outcomes or bioprosthetic valve failure 3 years after transcatheter aortic valve implantation.

METHODS

Patients with severe aortic stenosis were randomized to transfemoral transcatheter aortic valve implantation with NEO or S3 at 20 European centers. Clinical outcomes at 3 years are compared using Cox proportional or Fine-Gray subdistribution hazard models by intention-to-treat. Bioprosthetic valve failure is reported for the valve-implant cohort.

RESULTS

Among 739 patients, 84 of 372 patients (24.3%) had died in the NEO and 85 of 367 (25%) in the S3 group at 3 years. Comparing NEO with S3, the 3-year rates of all-cause death (hazard ratio, 0.98 [95% CI, 0.73-1.33]), stroke (subhazard ratio, 1.04 [95% CI, 0.56-1.92]), and hospitalization for congestive heart failure (subhazard ratio, 0.74 [95% CI, 0.51-1.07]) were similar between the groups. Aortic valve reinterventions were required in 4 NEO and 3 S3 patients (subhazard ratio, 1.32 [95% CI, 0.30-5.85]). New York Heart Association functional class ≤II was observed in 84% (NEO) and 85% (S3), respectively. Mean gradients remained lower after NEO at 3 years (8 versus 12 mm Hg; P<0.001).

CONCLUSIONS

Early differences between NEO and S3 did not translate into significant differences in clinical outcomes or bioprosthetic valve failure throughout 3 years.

REGISTRATION

URL: https://clinicaltrials.gov, Unique identifier: NCT03011346.

Interest & Impact

Downloads

2 since deposited on 10 Jul 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item